Myocardial Infarction with Non-obstructive Coronary Arteries (MINOCA) Patients Undergoing Cardiac Magnetic Resonance Imaging (CMR) by Adelaide Medical School
 1 
Myocardial Infarction with Non-obstructive Coronary 
Arteries (MINOCA) Patients Undergoing Cardiac 
Magnetic Resonance Imaging (CMR) 
 
A thesis submitted in partial fulfilment of the degree of 
BACHELOR OF HEALTH AND MEDICAL SCIENCES (HONOURS) 
In the Discipline of MEDICINE - Adelaide Medical School 
Faculty of Health Sciences 
 
University of Adelaide 
 
Manuscript written in the style of the European Heart Journal 
 
BY 





Word count: 4997  
 4 
ABSTRACT  
Myocardial infarction with non-obstructive coronary arteries (MINOCA) occurs in 10% of patients 
with myocardial infarction (MI). It is characterised by clinical evidence of MI in whom angiography 
does not show obstructive coronary artery disease (stenosis severity <50%), and thus there is no 
immediately apparent cause for the presentation. Cardiac magnetic resonance imaging (CMR) is a 
key diagnostic tool in the evaluation of patients presenting with MINOCA by providing a definite 
diagnosis (confirming myocardial necrosis) while also excluding other aetiologies. Despite the recent 
scientific interest in MINOCA, in clinical practice these patients are often discharged with minimal 
explanation for their MI diagnosis and limited understanding of their outcomes. To improve this 
knowledge gap, this study characterises patients presenting with MINOCA according to their CMR 
findings and describes the prevalence, patient characteristics and 12-month clinical outcomes 
(readmission and mortality) of those with (i) infarction/myocardial necrosis, (ii) non-ischaemic 
aetiology, and (iii) normal CMR findings. The null hypothesis to be tested is patient characteristics 
and clinical outcomes will not vary according to the CMR findings of MINOCA patients. In this 
retrospective analysis, 941 MINOCA patients were identified through the CADOSA registry between 
2012-2017, and 177 underwent CMR. The prevalence of CMR findings were: 9% had an infarct, 70% 
were non-ischaemic and 21% had a normal CMR. The infarct patients had the highest all-cause, 12-
month mortality (6%), followed by the non-ischaemic patients (2%) and 0% for the normal patients. 
Over 12 months, non-ischaemic patients had the highest cardiac readmission rate (18%), followed by 
normal patients (14%) and infarct patients (13%). Overall, CMR had a significant clinical impact in 
43% of patients by providing a new diagnosis and a specific diagnosis in 79% of patients. These 
findings highlight the heterogeneity associated with MINOCA patients and clinical outcomes, 
underscoring the need to individualise their management and follow-up.  





1.1 Coronary Artery Disease (CAD) 
Cardiovascular disease refers to heart and blood vessel related diseases such as stroke, peripheral 
vascular disease and, the most prevalent, coronary artery disease (CAD), which remains responsible 
for one-third of all deaths in individuals over 35 years.1 Two major forms of CAD include acute 
coronary syndrome (ACS) and stable angina.2 ACS is a collective term for clinical symptoms caused 
by myocardial ischaemia which includes acute myocardial infarction (AMI) and unstable angina.2 
Patients exhibiting clinical symptoms of ischaemia, but no evidence of myocardial necrosis are 
considered to have unstable angina,3 whereas myocardial necrosis (cell death) is indicative of AMI.4 
 
1.2 Acute Myocardial Infarction (AMI) 
Annually, 55,000 Australians experience AMI or heart attack, which equates to one every 10 
minutes.5 AMI commonly occurs as a result of coronary artery occlusion, ultimately causing 
haemodynamic disturbance.6 The pathophysiology of an AMI is reflected by causes of occlusion.7 
Atherosclerosis is a condition in which fatty deposits (plaques) build up along the inside walls of 
coronary arteries, which reduces the size of the arterial lumen.7 This restricts coronary blood flow to 
the myocardium causing prolonged myocardial ischaemia (myocardial tissues are compromised due 
to inadequate blood flow), ultimately leading to myocardial necrosis.6, 8, 9 Myocardial ischaemia can 
manifest as chest pain, termed ‘angina’.10  The atherosclerotic plaques can also suddenly rupture, 
causing the formation of a blood clot (coronary thrombosis) or vasospasm, resulting in coronary 
occlusion an thus severe acute ischaemia.10 Although atherosclerosis is the most common cause of 
AMI, accounting for at least 70% of fatal events7, 11 a combination of thrombosis, atheroma and 






1.2.1 Clinical criteria of AMI   
The Fourth Universal Definition of AMI devised by The European Society of Cardiology/ 
American College of Cardiology Joint Task Force clinically defines AMI by the following 
features:6   
a. Positive cardiac biomarker: Detection of a rise/fall of cardiac troponin (cTn) value 
above the 99th percentile upper reference limit  
b. Clinical evidence of MI, including any of the following 
i. Ischaemic symptoms (chest pain lasting >10 mins)  
ii. Ischaemic electrocardiography (ECG) changes 
Myocardial necrosis triggers the release of troponin (a protein specifically expressed by cardiac 
muscle cells) into the systemic circulation.6 Due to being a sensitive and specific cardiac biomarker 
of cardiac injury, troponin is considered the ‘gold standard’ method for assessing AMI, however it is 
not only used for an AMI diagnosis.13 Therefore, elevation of cTn must be interpreted in the context 
of clinical history and ECG findings.14 Abnormal cTn is considered when values are above the 99th 
percentile of the upper reference limit.6 Myocardial injury is defined by elevation of cTn when 
ischaemia is not present.14 Distinguished from myocardial infarction, myocardial injury occurs in the 
setting of cTn elevation in the absence of myocardial ischaemia, and a cause is specified for its 
presence.6 
1.2.2 Prognosis of AMI  
Patients who survive an AMI are at risk of further cardiovascular events including death, recurrent 
MI, heart failure, arrythmias, angina and stroke.15 Prognosis may vary widely between individuals 
according to their clinical profile, comorbidities and risk factors, thus risk stratification models are 
important in predicting prognosis.15 In developed countries, mortality rates following AMI have 
decreased over time, concomitantly with acute treatment, long-term secondary prevention and the 
common use of revascularisation procedures.16, 17 The 30 day mortality after AMI is around 2-3%.18 
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1.2.3 Diagnostic management of AMI  
Coronary angiography is an invasive procedure in which a catheter injects a contrast dye into the 
epicardial coronary artery to establish the site and extent of coronary blockages.19 Hence, it is the 
recommended investigation for the identification of coronary artery stenosis related to atherosclerotic 
CAD, and guides the therapeutic management of AMI.19 Coronary vessels narrowed at least 50% are 
termed ‘obstructive CAD’20 which accounts for a significant proportion of myocardial infarcts, hence 
the term ‘MICAD’ (Myocardial Infarction with Coronary Artery Disease).20 The management of 
MICAD patients is well defined and is focused on alleviating atherothrombotic processes that 
obstruct coronary blood flow through revascularisation therapies (i.e. stenting) and use of secondary 
prevention medications.20   
 
In the past, patients with a clinical criteria for STEMI (ST-Elevation-MI) were often labelled as 
having false-positive diagnosis when obstructive atheroma or thrombosis was absent on 
angiography.21 Consequently, implying the absence of AMI despite clinical presentation often 
enabled no further diagnostic investigation or appropriate cardiac therapy.22 To reduce this diagnostic 
error, the new clinical entity MINOCA (Myocardial Infarction with Non-Obstructive Coronary 
Artery Disease) was devised.22 
 
1.3 Myocardial Infarction with Non-Obstructive Coronary Artery Disease (MINOCA) 
Approximately 10% of patients with AMI do not reveal obstructive CAD on angiography,23 so the 
underlying pathophysiological processes are not immediately identified, a diagnosis referred to as 
MINOCA.24 This entity has become increasingly recognised through the frequent utilisation of 
coronary angiography during an AMI ultimately surging a recent interest in these patients.24 This 
intriguing subgroup is characterised by clinical evidence of AMI with nonobstructive coronary 
arteries on angiography (stenosis severity <50%).20 Potential underlying mechanisms include 
coronary causes such as plaque disruption and coronary artery spasm; non-ischaemic disorders such 
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as myocarditis, takotsubo cardiomyopathy (TTC) and other cardiomyopathies.25 These patients are 
often discharged with minimal explanation for their AMI, limited therapies and lack of follow-up.24  
 
1.4 Types of AMI  
The Fourth Universal Definition further classifies AMI into 5 types, outlined below, based on 
pathological, clinical and prognostic differences, along with different treatment strategies.6  
 
MINOCA comprises 5-20% of all type I AMI with atherosclerotic plaque disruption being a frequent 
cause.6 It is also important to consider type II AMI as it is the most common cause of MINOCA,6 
such as coronary artery spasm and thromboembolism.26 
 
1.5 Clinical Features and Risk Factors of MINOCA  
Studies have revealed that MINOCA patients cannot be delineated from those with MICAD based on 
clinical characteristics or risk factors.24 Cardiovascular risk factors are similar between both groups, 
however a comparative study revealed that hyperlipidemia is less likely in those with MINOCA 
compared to MICAD patients (21% vs. 32% respectively).25 In comparison to those with MICAD, 
MINOCA patients are younger and more often women (40% vs. 25% respectively), despite sharing 
Type  Definition  
I Infarction due to ischaemia from a primary coronary event such as atherosclerotic plaque 
disruption (rupture or erosion). 
II Ischaemic myocardial injury in the context of a mismatch between oxygen supply and 
demand. This can be caused by coronary spasm, coronary embolism, arrhythmia, anaemia, or 
hypotension. 
III Sudden cardiac death with symptoms suggestive of myocardial ischaemia, such as new 
ischaemic ECG changes, but which produces death before a blood sample can be obtained or 
when death occurs during the lag period before serum markers appear in the blood. 
IVa Infarction resulting from percutaneous coronary intervention. 
IVb Infarction from stent thrombosis. 
V Infarction due to ischaemia related to coronary artery bypass grafting.  
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many other clinical features.25 More specifically, 55 years was calculated to be the mean age of 
MINOCA patients while MICAD patients typically range between 58.8 and 61.2 years.25 
 
1.6.1 Diagnosis of MINOCA  
A MINOCA diagnosis is made for patients with a clinical presentation of AMI (according to the 
Universal Definition aforementioned)6, 27 in whom angiography does not show obstructive CAD and 
there is no immediately apparent cause for the presentation.24 This is an important distinction to make, 
as AMI is a clinical diagnosis, some patients may have fulfilled criteria for AMI but may have 
experienced a disorder that ‘mimics’ AMI.24 A common example of this is myocarditis (inflammation 
of the heart muscle, often caused by a virus) where a patient can present with fever, pleuritic chest 
pain, ECG changes and troponin elevation.24 In this situation, an angiography is performed to rule 
out CAD and reveals non-obstructive CAD.24 The diagnosis is myocarditis and the patient should not 
be considered MINOCA.24 In contrast, a patient with no virus symptoms or fever who presents with 
pleuritic chest pain, ECG and troponin elevation and reveals non-obstructive CAD should be 
diagnosed as MINOCA.24 It is in this context that MINOCA is considered a ‘working diagnosis’, 
analogous to heart failure.26 This flags the necessity to evaluate the patient for the potential underlying 
cause of this presentation.24 
 
1.6.2 Using Cardiovascular Magnetic Resonance Imaging (CMR) in MINOCA 
Given the range of aetiologies that can account for MINOCA presentations, further investigation to 
identify underlying causes is important if effective therapy is to be instituted.24 The characterisation 
of myocardial and microvascular injury in MINOCA patients can be completed by CMR.28 The high 
tissue contrast and resolution of this diagnostic tool allows for precise evaluation of myocardial 
structure and function.6 Late gadolinium enhancement (LGE-CMR) uses contrast agents for the 
assessment of myocardial perfusion and prior MI (increase in extracellular space associated with the 
fibrosis).6 As little as 1 gram of subendocardial infarction can be detected by localised delay in 
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contrast enhancement.29 CMR is also able to determine acute myocardial injury from chronic through 
identifying the presence and extent of myocardial oedema/inflammation.6 Areas of scarring is 
enhanced by LGE contrast agents washing from the myocardium with increased extracellular space 
such as fibrosis.6 Fibrosis scars extending from the subendocardium to the epicardium are usually 
ischaemic.6 Conversely, a typical non-ischaemic scar is present in the epicardium, in the mid-wall, or 
at the insertion points of the right ventricle.6  
 
Further, CMR is able to identify the cause in approximately 90% of MINOCA patients26 and is used 
as the benchmark non-invasive method to diagnose non-coronary conditions such as myocarditis and 
other cardiomyopathies.30 In a study by Dastidar et al.,31 CMR provided a definitive diagnosis in 70% 
of MINOCA patients, ultimately providing a new diagnosis in 54% of patients and a change in 
management in 41%. Thus, the ESC’s task force and various experts recommends the utilisation of 
CMR for evaluating underlying pathogenesis of MINOCA patients.25, 26, 30 
 
1.7 Management and Prognosis of MINOCA  
Whilst treatment strategies are well defined for AMI patients, there are currently no randomised 
clinical trials investigating different treatment strategies for MINOCA patients. Observational data 
from the SWEDEHEART (the Swedish Web-system for Enhancement and Development of 
Evidence-based care in Heart disease Evaluated According to Recommended Therapy) Registry 
revealed a 23%, 18%, 14% and 10% reduction in major adverse cardiovascular events in MINOCA 
patients with statin, angiotensin-converting enzyme inhibitor/angiotensin-receptor blocker, beta 
blockers and dual antiplatelet therapy, accordingly.32 The ESC suggests empiric treatment with 
aspirin and statins.26 Additionally, it is proposed that calcium channel blockers are used for 
vasospasm if the underlying mechanisms include thromboembolism, coronary spasm and coronary 
plaque disruption.26  
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The prognosis of patients with MINOCA is guarded and depends on the underlying cause, but overall 
is not a benign condition that should be underscored.9 In comparison to MICAD patients, those with 
MINOCA have a better prognosis, however long-term cardiovascular events is still important to 
recognise as MINOCA patients are younger and have fewer comorbidities.25, 33A systematic review 
by Pasupathy et al.25 revealed an in-hospital and 12-month all-cause mortality of 1.1% and 3.5% 
accordingly. These values are similar to the ANZAC (All New Zealand Acute Coronary Syndrome) 
study34 reporting a 12-month mortality of 3.2%, and the SWEDEHEART study32 reporting a 4 year 
mortality of 13%.  The prominent contributor of mortality is non-CVD death.34 In addition to 
mortality, hospitalisation rates and symptom burden should be also be considered in MINOCA 
patients. Grodzinsky et al.9 revealed that 25% of patients with MINOCA had ongoing post-infarct 
angina at 12 months, similar to MICAD patients. In a multicenter, observational cohort study of older 
patients with AMI (≥65 years), 38% of MINOCA patients were re-hospitalised for AMI (1%), heart 
failure (6%), stroke (2%) and other cardiac conditions.35 In comparison to MICAD patients, those 
with MINOCA are less likely to be satisfied with their ongoing treatment and more likely to have a 
poorer quality of life.36  
 
1.8 Significance of research   
Establishing MINOCA as a diagnostic entity has initiated a journey in improving the quality of care 
and understanding of this disorder.24 Despite investigations such as ECG, echocardiography and 
coronary angiography, there remains a challenge of establishing a diagnosis on clinical grounds.30 
This difficulty has led to MINOCA patients being often overlooked in contemporary clinical practice. 
Further, the wide scope of underlying causes warrants more research to understand how MINOCA 
patients can be characterized (both on prognosis and clinical features) according to their diagnostic 
workup findings. An important next step includes a multicenter randomised controlled trial 
investigating secondary prevention therapies on MINOCA patients.37 It is important to note that the 
use of CMR has a significant role in providing a definite diagnosis while also excluding other 
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aetiologies in MINOCA patients.26 Therefore, this research is important to emphasise the significance 
of CMR in MINOCA patients whilst also being the first study to evaluate characteristics on the 
prognosis of MINOCA patients who had CMR in South Australia. 
 
1.9 Aims and Hypothesis  
This study aims to characterise patients presenting with MINOCA according to their CMR findings 
and describe the prevalence, patient characteristics and 12-month clinical outcomes (mortality and 
re-hospitalisations) of those with (i) evidence of infarction (i.e. myocardial cell death), (ii) evidence 
of non-ischaemic aetiology (i.e. myocarditis), and (iii) normal CMR findings. Accordingly, the null 
hypothesis to be tested is patient characteristics and clinical outcomes will not vary according to the 

















2.0 METHODS & MATERIALS   
All protocols for this study were subject to prior approval by the Central Adelaide Local Health 
Network (CALHN) Human Research Ethics Committee (HREC) under the CADOSA (Coronary 
Angiogram Database of South Australia) Registry, HREC Approval Number: HREC/15/TQEH/252.  
 
2.1 Study Design  
2.1.1 Data collection  
CADOSA Registry: The CADOSA registry was established in 2012 and is a state-wide database of 
all consecutive patients undergoing coronary angiography procedures in South Australian public 
hospitals (The Queen Elizabeth Hospital, Royal Adelaide Hospital, Lyell McEwin Hospital, Flinders 
Medical Centre & Calvary Hospital). A detailed case report form, compatible with the American 
College of Cardiology CathPCI Registry, is completed for all patients enrolled in the Registry.  Data 
is captured via an opt-out consent approach. CADOSA data was obtained for patients undergoing 
coronary angiography between 2012-2017 for AMI and included data on patient demographics, 
clinical characteristics, angiography findings, medications and in-hospital events. This data was 
provided following authorisation by the CADOSA Data Custodian for the purpose of this analysis.  
 
From the overall CADOSA AMI data, consecutive patients with AMI and non-obstructive CAD 
during 2012-2017 were further reviewed to capture additional data not contained in the CADOSA 
Registry. This included an evaluation of the clinical context of cardiac troponin T (cTnT) elevation, 
including obtaining all cTnT results during the admission, obtain MRI findings, echo findings and 






2.1.2 Clinical Criteria – AMI  
The CADOSA Registry identifies AMI patients according to the Fourth Universal Definition of AMI 
devised by The European Society of Cardiology/American College of Cardiology Joint Task Force:6  
Positive cardiac biomarker (detection of a rise/fall of cardiac troponin value above the 99th percentile 
upper reference limit), ischaemic symptoms (chest pain lasting >10 mins) and ischaemic 
electrocardiography (ECG) changes. 
 
2.1.3 MINOCA Study Group  
The MINOCA study group included MINOCA patients identified in the CADOSA Registry 
undergoing CMR either during their hospitalisation, or at the next available booking.  
 
Inclusion criteria  
(i) Confirmed clinical diagnosis of AMI and undergoing coronary angiography 
(ii) Non-obstructed coronary arteries (stenosis severity <50%) on angiography 
(iii) Troponin elevation above 90ng/ml 
(iv) CMR undertaken 
Exclusion criteria  
(i) Patients undergoing coronary angiography with MICAD  
(ii) Patients undergoing coronary angiography following cardiac arrest 
(iii) Patients undergoing coronary angiography with insufficient data recorded in the 
registry 
(iv) MINOCA patients not undergoing CMR or with troponin elevation below 90ng/ml 





2.2 Collection of Prognosis Data 
Outcomes for patients were obtained following review of hospital administrative and electronical 
medical records. The outcomes collected included all-cause mortality and re-hospitalisation. In and 
out of hospital deaths occurring 12-months post discharge were identified. Re-hospitalisation data 
was collected for 12 months post discharge and defined as cardiac and non-cardiac readmission to 
any South Australian public hospital, based on the primary diagnosis recorded for the admission. 
 
Patients were classified as having experienced: 
All-cause mortality: Identified as a death occurring in hospital or out of hospital regardless of the 
cause of death. 
Cardiac readmission: Any cardiac readmission over 12 months. If a patient experienced both a 
cardiac and non-cardiac readmission, they were only classified as a cardiac readmission. 
Non-cardiac readmission: Any non-cardiac readmission over 12 months but no cardiac 
readmissions.  
Additionally, a composite all-cause readmission outcome was collected reflecting patients with any 
cardiac or any non-cardiac readmission over 12 months. 
 
2.3 CMR classification/Diagnosis 
 
2.3.1 Pre-CMR Classification/Diagnosis 
Pre-CMR diagnosis was determined by medical record documentation of the clinician’s suspected 
diagnosis which was based on a composite of clinical, biomarkers, ECG, echocardiographic and 
angiographic information. This information was used to then classify MINOCA patients into the 




2.3.2 Post-CMR Classification/Diagnosis  
All CMRs undertaken in relation to the AMI admission for MINOCA patients were reviewed and 
patients were classified into one of the following three groups based on the CMR diagnosis in 
conjunction with the clinical context:  
Infarction: CMR confirmed MI was diagnosed by territorial subendocardial and/or transmural LGE. 
Non-ischaemic: CMR confirmed cardiomyopathy: myocarditis, TTC or other cardiomyopathy.  
Normal: Structurally normal heart, defined as no regional wall motion abnormality, no myocardial 
oedema, no myocardial LGE in left ventricular. 
The CMR diagnosis was corroborated in conjunction with a MINOCA expert. 
 
2.4 Primary outcomes 
The primary outcomes for this study were 
(1) Prevalence of CMR confirmed infarction (i.e. myocardial cell death), non-ischaemic 
diagnoses (i.e. myocarditis), and (iii) normal cMRI findings.  
(2) Comparison of clinical features and prognostic outcomes (mortality and readmission) of 
MINOCA patients according to their CMR diagnosis 
 
2.5 Statistical Analysis  
Data for continuous variables are presented as mean ± standard deviation. Categorical variables are 
presented as frequencies and percentages. Clinical data and prognosis data were analysed for the 
overall study group and then compared between the three post-CMR classification/diagnosis groups. 
Comparisons were performed using linear or logistic models according to the dependent outcome 
being either continuous or binary and the CMR diagnosis (infarct, ischaemic or normal) being the 
categorical predictor variable.  A p-value of <0.05 was considered statistically significant. All 
analyses were performed using SPSS Version 25 for MacOS Mojave. 
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3.0 RESULTS  
A total of 9585 patients with AMI and non-obstructive CAD during 2012-2017 were identified in 
CADOSA, of which 90% (n=8644) were excluded for having evidence of MICAD (n= 7725), minor 
troponin rise (n= 422), cardiac arrest (n= 489) and insufficient data (n= 8). The remaining 10% (n= 
941) of patients were considered MINOCA but only 23% (n= 218) of these patients had undergone a 
CMR. A total of 177 MINOCA patients were included into the study as 41 patients had insufficient 
CMR data. The prevalence of the post-CMR classification/diagnosis was: 9% (n= 16) had an infarct, 
















Figure 1. Retrospective analysis profile for MINOCA patients undergoing CMR between 2012-2017.  
 
 
9585 patients identified in CADOSA 
Evidence of MICAD (Stenosis severity ≥ 50%) 
(n= 7725) 
(n= 
Minor troponin rise (<90ng/ml) (n= 422) 
Cardiac arrest patients (n= 489) 
941 (10%) MINOCA patients 
No CMR (n=723) 
 
 n=  218 MINOCA patients 
16 (9%) 





Insufficient data (n= 8) 
Insufficient CMR data (n=41) 
 
 n=  177 (19%) MINOCA patients 
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3.1. Baseline data  
 
3.1.1. Baseline Clinical Characteristics   
All data presented is related to the final MINOCA group with CMR findings available (n=177). 
Baseline clinical characteristics for MINOCA patients undergoing CMR is summarised in table 1. 
The mean age overall was 58±16 years, where 62% of the cohort were female. Compared to the non-
ischaemic group, the infarct group were on average older (66±13 vs. 57±16, p<0.05) and compared 


















Table 1. Baseline clinical characteristics of MINOCA patients undergoing CMR. AMI: Acute 
myocardial infarction, CAD: coronary artery disease, COPD: Coronary obstructive pulmonary 
disease.  
Baseline Clinical Characteristics 
  Overall  Infarct Non-
ischaemic 
Normal P-value 
  (n= 177)  (n=16)  (n=124) (n=37) 














  66 
(13) 
  57 
(16) 
  57 
(16) 
  0.037* 0.059 0.984 





  78 
(13) 
  77 
(19) 
  85 
(18) 
  0.892 0.241 0.061 




  158 
(10) 
  169 
(11) 
  165 
(8) 
  0.007* 0.05* 0.156 
Ethnicity 
Indigenous/Torres 
Strait Islander  
3 2% 0 0% 2 2% 1 3% 0.999 0.999 0.670 
Cardiac risk factors 
Smoker 42 25% 2 13% 33 28% 7 19% 0.239 0.604 0.310 
Hypertension 81 48% 11 69% 50 43% 20 54% 0.058 0.322 0.230 
Dyslipidaemia  71 41% 10 62% 50 42% 11 30% 0.129 0.029* 0.184 
Diabetes Mellitus  21 12% 3 19% 10 8% 8 22% 0.183 0.813 0.028* 
Previous Cardiac History 
Prior AMI 9 5% 2 13% 6 5% 1 3% 0.244 0.195 0.566 
Prior heart failure  7 4% 1 6% 4 3% 2 5% 0.562 0.903 0.563 
Family CAD  60 37% 3 21% 46 40% 11 32% 0.181 0.452 0.402 
Prior Angiogram  11 13% 2 29% 7 12% 2 11% 0.241 0.275 0.874 
Peripheral Artery 
Disease 
3 2% 0 0% 3 3% 0 0% 0.999 - 0.998 
Comorbidities 
Depression 43 25% 4 27% 32 26% 7 21% 0.971 0.639 0.503 
Sleep Apnoea 2 3% 0 0% 1 2% 1 6% 0.999 0.999 0.415 
COPD  15 9% 1 7% 10 8% 4 11% 0.824 0.611 0.576 
Cerebrovascular 
Disease 
9 5% 0 0% 8 7% 1 3% 0.999 0.999 0.381 
Current dialysis  1 1% 0 0% 0 0% 1 3% - 0.999 0.996 
Asthma  30 18% 3 20% 21 17% 6 18% 0.800 0.845 0.968 
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3.1.2 Discharge medication  
Discharge medications pre-CMR for MINOCA patients are demonstrated in table 2. The infarct group 
received more ticagrelor (25%) in comparison to the non-ischaemic group (4%, p<0.05) and normal 
group (3%, p<0.05). The normal group were prescribed more calcium channel blockers compared to 
the non-ischaemic group (24% vs. 9%, p<0.05).  
 
Table 2. Discharge medication pre-CMR for MINOCA patients undergoing CMR. ACE inhibitors: 
angiotensin-converting-enzyme inhibitors, β- blockers: Beta blockers. 
Discharge Medication  
  Overall  Infarct Non-ischaemic Normal P-value 
  (n= 177)  (n=16)  (n=124) (n=37) 










Aspirin  92 52% 10 63% 61 49% 21 57% 0.321 0.697 0.42 
Clopidogrel  13 7% 2 13% 8 7% 3 8% 0.386 0.618 0.727 
Ticagrelor  10 6% 4 25% 5 4% 1 3% 0.05* 0.033* 0.71 
Statins 87 49% 9 56% 59 48% 19 51% 0.515 0.743 0.687 




23 13% 3 19% 11 9% 9 24% 0.227 0.657 
0.016* 
Nitrate  23 13% 4 25% 12 10% 7 19% 0.082 0.617 0.133 
Ace inhibitors 98 55% 9 57% 69 56% 20 54% 0.963 0.883 0.864 




receptor blocker  








3.2 Further diagnostic investigation  
Further diagnostic investigation and CMR parameters are outlined in table 3. The normal patients 
had a higher ejection fraction on CMR (65±12) compared to the infarct group (53±16, P<0.05) and 
the non-ischaemic group (49±18, P<0.05).   
 
Table 3. Further diagnostic investigation and CMR findings for MINOCA patients undergoing CMR. 
PE: Pulmonary embolism, Echo= Echocardiogram, Ef: Ejection fraction. 
Further diagnostic investigation  
  Overall  Infarct Non-ischaemic Normal P-value 
  (n= 177)  (n=16)  (n=124) (n=37) 




















  56 (8)   40 
(21) 






  53 
(16) 
  49 
(18) 
  65 
(12) 












3.3 12-month Outcomes 
 
3.3.1 All-cause mortality  
All-cause mortality within 1 month, 1-12 months and over 12 months are presented in figure 2. There 
were no in-hospital mortality events amongst all three groups. Within 1 month, mortality was only 
observed in the non-ischaemic group (1%). Although not statistically significant, within 1-12 months, 
the infarct group had the highest mortality (6%) followed by the non-ischaemic group (2%). Similar 
non-statistically significant results were seen across 12 months where the infarct group had the 













































All- cause mortality 
Overall Infarct Non-ischaemic Normal
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3.3.2. Cardiac and non-cardiac readmission within 1 month, 1-6 months and 6-12 months 
Cardiac and non-cardiac readmissions for all MINOCA patients are outlined in table 4. At 1 month, 
the overall cardiac readmission rate was 7% and 8% for non-cardiac readmissions. These rates were 
similar for the three groups. At 1-6 months, the overall cardiac and non-cardiac readmission rate were 
both 7%. Although not statistically significant, the infarct patients experienced no cardiac 
readmissions, but the non-ischaemic and normal patients did (7% and 8% respectively). At 6-12 
months, again the overall cardiac and non-cardiac readmission rate were both 7%. At this time point, 
these readmissions were experienced by the infarct and non-ischaemic patients only (6% each).  
 
Table 4. Cardiac and non-cardiac readmissions of MINOCA patients at 1 month, 1-6 months and 6-
12 months. 
Readmission 
  Overall  Infarct Non-
ischaemic 
Normal P- value 
  (n= 177)  (n=16)  (n=124) (n=37) 








Within 1 month 
All-cause  25 14% 2 13% 17 14% 6 16% 0.894 0.729 0.703 
Cardiac  12 7% 1 6% 8 7% 3 8% 0.975 0.815 0.727 
Non-cardiac  14 8% 1 6% 10 8% 3 8% 0.800 0.815 0.993 
Between 1-6 months 
All-cause  21 12% 1 6% 17 14% 3 8% 0.415 0.815 0.370 
Cardiac  12 7% 0 0% 9 7% 3 8% 0.999 0.999 0.863 
Non-cardiac  13 7% 1 6% 11 9% 1 3% 0.726 0.545 0.238 
Between 6-12 months 
All-cause  20 11% 2 13% 16 12% 2 5% 0.964 0.382 0.219 
Cardiac  8 7% 1 6% 7 6% 0 0% 0.922 0.998 0.998 




3.3.3. Cardiac and non-cardiac readmissions over 12 months  
Figure 3 demonstrates the cardiac and non-cardiac readmission of MINOCA patients over 12 months. 
Overall, 29% of patients experienced any admission, 16% of patients experienced only cardiac 
readmission and 18% of patients experienced only non-cardiac admissions.  There were no statistical 
significance differences amongst the readmissions data. 
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3.3.4 Cardiac readmission causes for MINOCA patients  
The cardiac readmission causes over 12 months is shown in figure 4. Angina accounted for half of 
cardiac readmissions (49%).  
 
Figure 4. Cardiac readmission causes for MINOCA patients within 12 months. MI: myocardial 


























3.3.5 Cardiac readmission causes according to CMR diagnosis  
The cardiac readmission causes for MINOCA patients according to their CMR diagnosis within 12 
months is presented in figure 5. The normal group experienced the most angina (11%), followed by 
the non-ischaemic group (10%) and no angina admissions for the infarct group. The only group to 
have recurrent MI was those with a non-ischaemic diagnosis (2%). The infarct group had the highest 
heart failure (5%) and stroke (6%) readmission compared to other groups. There were no statistical 
significances amongst the data. 
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3.4 Comparison of pre-CMR diagnosis to post-CMR diagnosis  
Comparison of pre-CMR to post-CMR diagnosis is demonstrated in figure 6. The pre-CMR diagnosis 
did not change in over half of patients following the CMR (indicated in blue). However, CMR 
provided a new diagnosis in 43% (n= 76) of patients. TTC was the most consistent diagnosis before 









 Takotsubo Myocarditis MI Other CM Normal 
Takotsubo 54 0 1 1 12 
Myocarditis 0 18 0 0 6 
MI 2 2 7 3 1 
Other CM 0 2 0 5 1 
Uncertain 8 27 8 2 17 
 


















4. DISCUSSION  
This study is the first to evaluate the prognosis of MINOCA patients according to their CMR 
diagnosis. It demonstrates that between 2012-2017, there were 941 MINOCA patients in South 
Australia and of these only 218 (23%) underwent CMR. Of the 177 patients with CMR data (58 ± 16 
years; 62% women) included in the study, CMR provided a specific diagnosis in 79% of patients. 
The prevalence was 9% (n=16) had an infarct, 70% (n= 124) were non-ischaemic and 21% (n= 37) 
had normal CMR results. 
 
The raised troponin in MINOCA patients with normal CMR is either indicative of myocardial injury 
or an alternate diagnosis. The prevalence of normal CMR (21%) is consistent with other studies, 
including a meta-analysis of 26 CMR studies investigating MINOCA (8-26%).25 With current 
techniques, LGE-CMR cannot detect myocardial injury below approximately 1 gram.38 Thus, the 
normal CMR appearance may be a result of necrotic myocytes dispersed over a larger area with no 
connecting island of cell death of sufficient size to be detected by LGE imaging. Further, it is possible 
that a proportion of patients with troponin elevation may also be a biochemical false positive.  
 
Additionally, studies such as Dastidar et al.31 have demonstrated the importance of performing early 
CMR (<2 weeks) in MINOCA patients to maximise diagnostic yield by capturing myocardial damage 
before healing occurs. This is important in reversible conditions such as myocarditis and TTC.31 In 
this study, the median time for CMR to be conducted after presentation was 3 days (interquartile 
range, 4 days) where 70% of patients had a CMR within 2 weeks, suggesting that perhaps timing may 
have been a factor in the remaining patients who had late CMR (>2 weeks). Management of normal 
CMR patients remains unclear as studies have yet to address this subgroup.26  
 
Prognostically, the study strengthens the growing evidence that the MINOCA population should not 
be viewed as a low risk subtype of MI. Overall at the 12-month point, mortality was 2% and the 
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overall readmission rate was 29% (Figure 2 & 3, respectively). Although not statically significant, 
the infarct patients had the highest all-cause, 12-month mortality (6%) followed by the non-ischaemic 
patients (2%) and none for the normal patients (Figure 2). Whilst it is plausible that the death in the 
infarct group was non-cardiac related, underlying disease progression cannot be excluded, 
underscoring that MINOCA patients require further attention in follow-up and secondary prevention 
measures.  
 
As with earlier studies, myocarditis accounts for the most common underlying pathology, contrary 
this study as 49 (28%) of patients were diagnosed with myocarditis on CMR and 64 (36%) with TTC 
(Figure 6). This is in contrast to earlier work by Assomull et al.39 who only reported one cause of 
TTC, but similar to a more recent study by Pathik et al.30 (27%). TTC patients often have on-going 
symptom burden and repeat TTC.40 As TTC patients accounted for 52% of non-ischaemic patients 
alone, this may explain why this subgroup had the highest 12-month cardiac readmission (18%, 
Figure 3). Further, over 12 months, the normal patients still experienced a moderate rate of cardiac 
readmission (14%) compared to a similar rate of 13% in the infarct group (Figure 3). A potential 
explanation is that the infarct patients are being diagnosed via CMR as having an ‘infarct’, and 
perhaps they were provided with more optimal secondary preventative measures and thus had similar 
readmission rate to the normal patient group. However, it should also be considered, as 
aforementioned, that the ‘normal’ CMR patients may have too little myonecrosis to be detected but 
still in-fact have suffered an infarct, leading to inadequate secondary preventative measures, and thus 
a high readmission burden, similar to that of infarct patients. This can be supported by these normal 
patients experiencing heart failure (5%) and the most angina (11%) (Figure 5).  
 
The data represented in figure 4 and 5 show that angina accounts for half of the cardiac readmission 
causes by non-ischaemic and normal patients. Therefore, perhaps strategies to reduce symptom 
burden is warranted for these patients. MINOCA patients should therefore receive close follow-up as 
 30 
the moderate rate of readmissions, dominated by repeat angina symptoms, reinforces the importance 
of establishing a correct diagnosis and regular follow-up. 
 
Overall, CMR had a significant clinical impact in 76 (43%) of patients by providing a new diagnosis 
(Figure 6). This figure was smaller, yet not considerably different to other publications such as 
Dastidar et al.30 (54%) and Assomull et al.39 (65%). This highlights the potential risk of 
underdiagnosing and therefore undertreating patients without the utility of the CMR findings. For 
example, if a patient received a clinical diagnosis of AMI but had evidence of myocarditis on CMR, 
this patient would not have received important treatments for myocarditis such as corticosteroids if 
managed purely on clinical grounds. Although collecting data on change in management was out of 
scope of the current study, it provides direction for future studies. A correct diagnosis is imperative 
for providing outpatient follow-up management, appropriate counselling and future risk stratification. 
 
Reflecting on the use of cardiac medications prescribed at discharge in conjunction with the post 
CMR diagnosis, only 63% of infarct patients received aspirin therapy, although clinical guidelines41, 
42 recommend all AMI patients should be given this antiplatelet medication (Table 2), Patients with 
a normal CMR may be considered to require less aggressive cardiac medication, however they 
received more aspirin, statins and nitrates compared to non-ischaemic patients (57% vs. 49%, 51% 
vs. 48% and 19% vs. 10%, respectively, Table 2). Additionally, the normal patients received the most 
ace inhibitor and/or angiotensin receptor blocker, another guideline recommended therapy for AMI 
patients, (78%) compared to the non-ischaemic and infarct patients (69% each) (Table 2). These 
inconsistencies can be explained by the medication being prescribed prior to CMR. Hence, the 
clinicians were treating the pre-CMR diagnosis rather than the CMR diagnosis.  Comparison of 
medications prescribed before and after CMR findings may provide better insights on how MINOCA 
patients are receiving treatment according to their CMR diagnosis. Future studies evaluating how 
CMR guided management impacts on prognostic outcomes is also warranted. It is important to also 
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note that the clinical guideline evidence for the use of cardiac secondary prevention measures has 
been generated largely from studies in MICAD patients and there is little data on the benefits of these 
measures specifically in MINOCA patients. This issue is currently being addressed in a randomised 
controlled trial in Australia and Sweden.43  
 
Several limitations merit consideration. Firstly, there may be a selection bias in this study. Patients 
were recruited based on if they had a CMR undertaken, and thus clinicians believed that further 
diagnostic investigation needed to be undertaken in these patients. Thus, a study where all MINOCA 
patients undergo a CMR would improve the generalisability of the findings and applicability in the 
real world. Secondly, another limitation involves the lack of diversity in patients due to sourcing them 
from South Australia only. Hence, it is recommended to widen the geographical sources for patients 
which will also increase sample size. To enhance the understanding of MINOCA patient outcomes, 
prognosis studies necessitate a larger sample size. A post-hoc power calculation using the cardiac 
readmission rates in this study for the infarct, ischaemic and normal patient groups (13%, 18% and 
14% respectively), estimate that over 800 patients in each group would be required to determine a 
statistically significant difference in outcomes. This type of study and sample size could be achieved 
through national or international collaborations.  
 
In addition to improving diagnostic certainty, the additional value of CMR in MINOCA patients 
could be further exemplified by documenting the impact both in terms of clinical and health service 
utilisation. Although identifying patients who had a change in diagnosis after CMR was important, it 
does not imply that a change in management occurred. Hence, investigating changes in length of 
hospital stay, changes in discharge medications, association with clinical outcomes, and the 
introduction and/or avoidance of additional invasive procedures can better capture the effects CMR 
can have on MINOCA patients beyond providing a diagnosis.  
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5. CONCLUSION  
It is important to identify the underlying cause of MINOCA for each patient to ultimately guide 
ongoing management and provide patient assurance and guidance on their condition. The study 
strengthens the evidence that CMR is a clinically relevant non-invasive imaging modality for the 
assessment of patients presenting with MINOCA by providing a specific diagnosis in 79% of patients. 
Additionally, CMR had a significant clinical impact in 76 (43%) of patients by providing a new 
diagnosis. Accordingly, there is scope for improved understanding of patients with a normal diagnosis 
on CMR and how this diagnostic tool can change management in MINOCA patients, and ultimately 
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